OraSure Technologies, Inc. (NASDAQ:OSUR) Stock Holdings Lifted by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP raised its position in shares of OraSure Technologies, Inc. (NASDAQ:OSURFree Report) by 8.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,906,687 shares of the medical instruments supplier’s stock after purchasing an additional 301,558 shares during the period. Dimensional Fund Advisors LP owned 5.32% of OraSure Technologies worth $32,035,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in OSUR. Illinois Municipal Retirement Fund acquired a new stake in OraSure Technologies in the third quarter valued at approximately $264,000. Barclays PLC lifted its position in shares of OraSure Technologies by 46.6% in the third quarter. Barclays PLC now owns 110,090 shares of the medical instruments supplier’s stock worth $653,000 after buying an additional 34,987 shares during the last quarter. New York State Common Retirement Fund lifted its holdings in OraSure Technologies by 358.8% in the 3rd quarter. New York State Common Retirement Fund now owns 88,411 shares of the medical instruments supplier’s stock worth $524,000 after purchasing an additional 69,142 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of OraSure Technologies by 28.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 727,617 shares of the medical instruments supplier’s stock worth $4,315,000 after buying an additional 162,462 shares during the period. Finally, Pathstone Family Office LLC bought a new stake in OraSure Technologies during the third quarter valued at about $80,000. 93.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on OSUR. Evercore ISI decreased their target price on OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating for the company in a research note on Thursday, April 4th. StockNews.com downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, May 9th. Finally, JPMorgan Chase & Co. cut their target price on shares of OraSure Technologies from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Monday, May 13th. Three investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, OraSure Technologies currently has a consensus rating of “Hold” and an average target price of $6.63.

Read Our Latest Stock Report on OSUR

OraSure Technologies Trading Up 0.6 %

Shares of NASDAQ:OSUR opened at $4.73 on Friday. The business’s 50 day moving average is $5.42 and its 200-day moving average is $6.72. The firm has a market capitalization of $349.83 million, a PE ratio of 15.77 and a beta of 0.23. OraSure Technologies, Inc. has a 1-year low of $4.38 and a 1-year high of $8.45.

OraSure Technologies (NASDAQ:OSURGet Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The medical instruments supplier reported $0.04 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.04. OraSure Technologies had a net margin of 7.50% and a return on equity of 7.68%. The firm had revenue of $54.10 million for the quarter, compared to the consensus estimate of $52.27 million. During the same quarter in the previous year, the company earned $0.37 earnings per share. The business’s revenue was down 65.1% compared to the same quarter last year. On average, sell-side analysts predict that OraSure Technologies, Inc. will post -0.12 EPS for the current year.

OraSure Technologies Profile

(Free Report)

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.

Featured Articles

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.